KLRK1 and pancreatic neoplasm: Compared to conventional NKG2D CAR-T cells, the 4/15NKG2D-CAR-T cells exhibit increased activation, degranulation, cytokine release, and cytotoxicity against IL-4–positive pancreatic cancer cells in both in vitro and in vivo models [105].